Vision - Slow the progression of, prevent, and cure Parkinson's disease in order to lessen personal and societal impact of the disorder
The overall goals of the program are: 1) Develop means to correlate risk factors and dysfunction associated with PD, 2) Develop means to identify risk factors for subsets of the affected population, 3) Correlate clinical phenotype and molecular underpinning and 4) Develop candidate therapeutics, based on identified molecular pathway intervention points, to halt progression and extend quality of life for the at-risk population.
The program develops means to ameliorate the effect of risk factors by: 1) preventing or delaying development of the cardinal motor signs of the condition that compromise performance and long-term health and 2) identification of preventions and therapeutics for currently diagnosed patients. Specific risk factors of interest are: chemical exposures, prolonged physiological stress, depression, traumatic injury to the head, disordered sleep architecture and dysautonomia.
Dr. Kenneth Marek Video
Institute for Neurodegenerative Disorders
Evaluating the Natural History of Prodromal PD in the PARS Cohort
Dr. Caroline Tanner
University of California, San Francisco
Persistent Organic Pollutants and Parkinson’s disease in Native Populations of Hawaii and Alaska
Dr. Paul Greengard
New P11 Biomarker Predicts Clinical Effectiveness of Antidepressant Drugs
Dr. Howard J. Federoff
University of California, Irvine
PGC-1α Therapy for Parkinson Neurodegeneration
Last updated Wednesday, June 14, 2017